» Articles » PMID: 23827400

Relation of Carotid Intima-media Thickness and Plaque with Incident Cardiovascular Events in Women with Systemic Lupus Erythematosus

Abstract

Patients with systemic lupus erythematosus (SLE) are at increased risk for cardiovascular (CV) disease. The aim of this study was to investigate the association between subclinical CV disease as measured by carotid intima-media thickness (IMT) and plaque using B-mode carotid ultrasound and incident CV events in a combined cohort of female patients with SLE. This was a prospective, 2-center observational study of 392 adult women with SLE and no previous CV events with a mean 8 years of follow-up. Incident CV events confirmed by clinicians were defined as angina, myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft, fatal cardiac arrest, transient ischemic attack, and cerebrovascular accident. Incident hard CV events excluded angina and transient ischemic attack. The mean age was 43.5 years, and most patients were Caucasian (77.3%). During follow-up, 38 patients had incident CV events, and 17 had incident hard CV events. Patients with incident hard CV events had higher mean carotid IMT (0.80 vs 0.64 mm, p <0.01) and presence of carotid plaque (76.5% vs 30.4%, p <0.01) compared with those without incident hard CV events. Baseline carotid IMT and presence of plaque were predictive of any incident hard CV event (hazard ratio 1.35, 95% confidence interval 1.12 to 1.64, and hazard ratio 4.26, 95% confidence interval 1.23 to 14.83, respectively), independent of traditional CV risk factors and medication use. In conclusion, in women with SLE without previous CV events, carotid IMT and plaque are predictive of future CV events. This suggests that carotid ultrasound may provide an additional tool for CV risk stratification in patients with SLE.

Citing Articles

Investigation of the relationship between hypertension and asymptomatic organ damage in patients with Sjogren's disease.

Bayraktar M, Toprak G, Tasci M Medicine (Baltimore). 2025; 103(52):e41041.

PMID: 39969371 PMC: 11688106. DOI: 10.1097/MD.0000000000041041.


Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the Clinician.

Semalulu T, Tago A, Zhao K, Tselios K Immunotargets Ther. 2023; 12:175-186.

PMID: 38089168 PMC: 10714964. DOI: 10.2147/ITT.S377076.


Antibodies against Phosphorylcholine-Implications for Chronic Inflammatory Diseases.

Frostegard J Metabolites. 2023; 13(6).

PMID: 37367878 PMC: 10301491. DOI: 10.3390/metabo13060720.


Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers.

Guzman-Martinez G, Maranon C Front Immunol. 2022; 13:974826.

PMID: 36420265 PMC: 9677819. DOI: 10.3389/fimmu.2022.974826.


Study of common hypertriglyceridaemia genetic variants and subclinical atherosclerosis in a group of women with SLE and a control group.

Fanlo-Maresma M, Esteve-Luque V, Pinto X, Padro-Miquel A, Corbella E, Candas-Estebanez B Lupus Sci Med. 2022; 9(1).

PMID: 35999016 PMC: 9403106. DOI: 10.1136/lupus-2022-000774.


References
1.
DAgostino Sr R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6):743-53. DOI: 10.1161/CIRCULATIONAHA.107.699579. View

2.
Parker B, Ahmad Y, Shelmerdine J, Edlin H, Yates A, Teh L . An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus. 2011; 20(14):1459-65. DOI: 10.1177/0961203311416695. View

3.
Skamra C, Ramsey-Goldman R . Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol. 2010; 5(1):75-100. PMC: 2839248. DOI: 10.2217/ijr.09.73. View

4.
Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald S, Rairie J, Tracy R . Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999; 42(1):51-60. DOI: 10.1002/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D. View

5.
Fardet L, Petersen I, Nazareth I . Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ. 2012; 345:e4928. PMC: 3408386. DOI: 10.1136/bmj.e4928. View